SecuritySYK / Stryker Corp. (863667101)
IndustrySurgical and Medical Instruments and Apparatus
Common Stock Shares Outstanding374,000,000 shares (as of 2018-03-31)
Total Insiders26
Total Directors12
Total Officers15

Stock Insider Trading (from SEC Form 4)

Stryker Corp. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

SYK / Stryker Corp. insiders include Doliveux Roch, Suri Rajeev, and STRYKER RONDA E, Carpenter Lonny J, PARFET WILLIAM U, Boehnlein Glenn S, Sagar Bijoy, Datar Srikant, Fink M Kathryn, Owen Katherine Ann, BRAINERD MARY K FRANCESCONI LOUISE, Becker Yin C, Lobo Kevin, Benscoter Steven P, Scannell Timothy J, Golston Allan C., Subrahmanian Ramesh, Hutchinson Michael David, Berry William E Jr, Silvernail Andrew K, McLean Graham A, McCoy Sherilyn S, Floyd David, Menon Viju, COX HOWARD E JR, .

Insider Roster

Insider Dir Off 10% Shares Owned
Carpenter Lonny J Group President
X 104,437
Doliveux Roch Director
X
BRAINERD MARY K Director
X
Datar Srikant Director
X
Suri Rajeev Director
X
McCoy Sherilyn S Director
X
STRYKER RONDA E Director
X
Silvernail Andrew K Director
X
Golston Allan C. Director
X
FRANCESCONI LOUISE Director
X
Menon Viju Group President
X 0
Floyd David Group President
X 33,597
Scannell Timothy J Group President
X 135,723
Owen Katherine Ann VP, Strategy and IR
X 8,607
Boehnlein Glenn S VP, Chief Financial Officer
X 4,822
COX HOWARD E JR Director
X 525,452
Sagar Bijoy VP, Chief Information Officer
X 4,854
McLean Graham A President, Asia-Pacific
X 5,670
Lobo Kevin Chairman and CEO, Director
X X 49,887
Hutchinson Michael David General Counsel
X 12,677
Fink M Kathryn VP, Chief HR Officer
X 6,382
Berry William E Jr VP, Corporate Controller
X 1,627
Becker Yin C VP, Comm. and Public Affairs
X 10,761
PARFET WILLIAM U Director
X
Subrahmanian Ramesh Group President
X
Benscoter Steven P VP, Human Resources
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-05-04 4 Carpenter Lonny J S X D 166.4206 -5,000 104,437 17,380,468
2018-05-01 4 Scannell Timothy J F D 169.42 -668 135,723
2018-05-01 4 Scannell Timothy J M D 1,355 136,391
2018-05-01 4 Floyd David F D 169.42 -352 33,597
2018-05-01 4 Floyd David M D 723 33,949
2018-05-01 4 Carpenter Lonny J F D 169.42 -591 109,437
2018-05-01 4 Carpenter Lonny J M D 1,355 110,028
2018-04-30 4 Doliveux Roch P D 171.2692 43 19,560 3,350,026
2018-04-18 4 Owen Katherine Ann S X D 165 -2,651 8,607 1,420,155
2018-04-16 4 Boehnlein Glenn S S X D 160 -750 4,822 771,520
2018-03-26 4 Owen Katherine Ann S X D 160 -103 11,216 1,794,560
2018-03-21 4 Golston Allan C. M D 720 9,027
2018-03-21 4 Silvernail Andrew K M D 720 1,902
2018-02-28 4 Silvernail Andrew K G D -470 1,182
2018-03-21 4 Datar Srikant M D 720 9,277
2018-03-21 4 STRYKER RONDA E M D 720 23,767,763
2018-03-21 4 Carpenter Lonny J F D -8,234 108,623
2018-03-21 4 Carpenter Lonny J A D 19,892 116,857
2018-03-22 4 Becker Yin C S X D 162.9174 -1,804 10,761 1,753,154
2018-03-22 4 Becker Yin C S X D 162.8809 -2,044 12,565 2,046,599
2018-03-21 4 Becker Yin C F D -2,041 14,609
2018-03-21 4 Becker Yin C A D 4,142 16,650
2018-03-21 4 Berry William E Jr F D 166.51 -152 1,627
2018-03-21 4 Berry William E Jr M D 531 1,779
2018-03-21 4 Berry William E Jr F D 166.51 -186 1,248
2018-03-21 4 Berry William E Jr M D 647 1,434
2018-03-21 4 Berry William E Jr F D 166.51 -177 787
2018-03-21 4 Berry William E Jr M D 618 964
2018-03-21 4 Boehnlein Glenn S F D 166.51 -313 5,528
2018-03-21 4 Boehnlein Glenn S M D 904 5,841
2018-03-21 4 Fink M Kathryn F D 166.51 -167 6,382
2018-03-21 4 Fink M Kathryn M D 582 6,549
2018-03-21 4 Floyd David F D 166.51 -10,502 33,151
2018-03-21 4 Floyd David A D 21,550 43,653
2018-03-21 4 Hutchinson Michael David F D 166.51 -2,991 12,677
2018-03-21 4 Hutchinson Michael David A D 7,182 15,668
2018-03-22 4 Lobo Kevin S X D 162.8966 -39,808 49,887 8,126,423
2018-03-21 4 Lobo Kevin F D 166.51 -39,732 89,695
2018-03-21 4 Lobo Kevin A D 80,669 129,427
2018-03-21 4 McLean Graham A M D 621 5,670
2018-03-21 4 McLean Graham A M D 609 5,049
2018-03-23 4 Owen Katherine Ann S X D 160.2311 -2,572 11,319 1,813,656
2018-03-21 4 Owen Katherine Ann F D 166.51 -3,269 13,891
2018-03-21 4 Owen Katherine Ann A D 8,728 17,160
2018-03-21 4 Sagar Bijoy F D 166.51 -1,537 4,854
2018-03-21 4 Sagar Bijoy A D 4,422 6,391
2018-03-21 4 Sagar Bijoy F D 166.51 -302 1,969
2018-03-21 4 Sagar Bijoy M D 612 2,271
2018-03-21 4 Scannell Timothy J F D 166.51 -14,098 134,974
2018-03-21 4 Scannell Timothy J A D 29,284 149,072
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

14h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

14h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

Related News Stories

Tracking David Tepper's Appaloosa Management Portfolio - Q1 2018 Update

20h seekingalpha
This article is part of a series that provides an ongoing analysis of the changes made to David Tepper’s 13F portfolio on a quarterly basis. It is based on Appaloosa Management’s regulatory 13F Form filed on 05/15/2018. Please visit our Tracking David Tepper’s Appaloosa Management Portfolio series to get an idea of his investment philosophy and our previous update for the fund’s moves during Q4 2017. (1494-1)

Wright Medical Improving, But At A Choppy Pace

2018-05-10 seekingalpha
Wright Medical beat expectations for the first quarter, with ongoing strength in the shoulder business driving the outperformance. (6-0)

Tracking Yacktman Asset Management Portfolio - Q1 2018 Update

2018-05-10 seekingalpha
This article is part of a series that provides an ongoing analysis of the changes made to Yacktman's 13F stock portfolio on a quarterly basis. It is based on Yacktman Asset Management's regulatory 13F Form filed on 05/09/2018. Please visit our Tracking Yacktman Asset Management series to get an idea of his investment philosophy and our previous update for the fund's moves during Q4 2017. (561-3)

Zacks.com featured expert Kevin Matras highlights: Waste Connections, Roper, Stryker and Hi-Crush

2018-05-09 zacks
Chicago, IL – May 9, 2018 - Stocks in this week’s article include: Waste Connections (WCN - Free Report) ,Roper Technologies (ROP - Free Report) , Stryker (SYK - Free Report) and Hi-Crush Partners (HCLP - Free Report) . Kevin Matras screens for companies showing their 'first' profit and explains why they are ones to watch. (13-0)

Merrill Lynch Makes Big Changes to Super-Safe Defensive Portfolio

2018-05-01 247wallst
If you get the feeling that every rise in the market is being sold by institutional investors, you may not be far off base. It has become obvious since the massive February sell-off that the “buy the dip” mentality that seemed to last forever may be over. With a plethora of concerns, not the least of which are rising interest rates, the potential for trade war tariffs, geopolitical issues and a host of other potential issues muddying the water, it may be time to play it safe. (80-0)